Conclusion
105. The Committee believes the Community
patent, a single patent which is valid throughout the Community,
would have advantages over the present system of European and
national patents. The success of the system depends firstly, as
we said in our 1986 Report, on keeping the costs down. A practical
solution has to be found to the question of the number and extent
of translations. There must also be judicial arrangements which
will command the confidence of industry. The Community patent
has to be sufficiently attractive to industry and able to compete
alongside national patents and the European patent. If not, it
will remain a white elephant which no-one will want. It is clear
to the Committee that there is substantial interest in and support
for a Community patent within industry at the present time. A
major political push and a preparedness to compromise on the language
question are needed if the idea is to become a reality.
RECOMMENDATION
106. The Committee considers that the
Green Paper on the Community Patent and the Patent System in Europe
raises important questions to which the attention of the House
should be drawn and makes this Report to the House for information.
9 COPAC could request a preliminary ruling whenever
there was a risk of inconsistent interpretation between the CPC
and the EC Treaty. If a Member State or the Commission considered
that there was such an inconsistency resulting from a decision
of COPAC, it too could seek a ruling. Certain national courts
acting as Community patent courts could also ask the Court of
Justice for a ruling on the interpretation of the Convention's
provisions on jurisdiction. Back
10
The Court of first Instance has jurisdiction to hear appeals under
the Community Trade Mark Regulation. Appeals are dealt with first
by Appeal Boards within OHIM. It is far too early to say how that
is going to work. Cases have yet to emerge from the appeal process
within OHIM. Back
11
Currently 50% of the renewal fee is passed on to the EPO as a
contribution towards its costs. Back
12
Case C-350/92, Spain v. Council: [1995] E.C.R. I-1985,
at para. 23. Back
13
Opinion 1/94: [1994] E.C.R.
I-5267. The matter arose in relation to the definition of the
extent of the Community's and the Member States' participation
in the TRIPS Agreement. Back
14
Council Regulation (EEC) No 1768/92 concerning the creation of
a supplementary protection certificate for medicinal products,
OJ L 182,2.7.1992, and Regulation (EC) No 1610/96 of the EP and
Council concerning the creation of a supplementary protection
certificate for plant protection products, OJ L 198, 8.8.1996.
In our 4th Report 1993-94, Patent Protection for Biotechnological
Inventions, we considered a proposal for a Directive, currently
before the European Parliament, which, if adopted, would set out
the conditions in which a patent may be obtained for a biotechnological
invention. Back